<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04688723</url>
  </required_header>
  <id_info>
    <org_study_id>METCZ20200196</org_study_id>
    <nct_id>NCT04688723</nct_id>
  </id_info>
  <brief_title>Dual Therapy With Dabigatran/Ticagrelor Versus Dual Therapy With Dabigatran/Clopidogrel in ACS Patients With Indication for NOAC Undergoing PCI</brief_title>
  <acronym>RE-DUAL PCI</acronym>
  <official_title>RE-DUAL PCI Real Life Registry Dual Therapy With Dabigatran/Ticagrelor Versus Dual Therapy With Dabigatran/Clopidogrel in ACS Patients With Indication for NOAC Undergoing PCI</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zuyderland Medisch Centrum</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Zuyderland Medisch Centrum</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A real world registry to compare dual therapy with Dabigatran/Ticagrelor to dual therapie&#xD;
      with Dabigatran/Clopidogrel in patients with an indication for NOAC undergoing PCI in the&#xD;
      setting of ACS. Hypothesis: Dual therapy with Dabigatran/Ticagrelor will be non-inferior in&#xD;
      reducing the risk of bleeding compared to Dual therapy with Dabigatran/Clopidogrel (RE-DUAL&#xD;
      PCI trial based) in patients with an indication for NOAC undergoing PCI in the setting of&#xD;
      ACS. Thromboembolic events, stent thrombosis and death will be evaluated for estimation of&#xD;
      events between both groups. Data will be pooled for this secondary endpoint with data from&#xD;
      the upcoming WOEST-3 trial to compare both treatments.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The REDUAL PCI Registry will we be an open-label multicenter registry based randomised&#xD;
      controlled trial (RBRCT) within the ZON-HR collaboration in 4 of the 6 centers in the&#xD;
      Netherlands: Maastricht Universitair Medisch Centrum (Maastricht), Zuyderland (Heerlen and&#xD;
      Sittard), Vie Curi (Venlo) and Radboud Medisch Centrum (Nijmegen). Isala (Zwolle) and&#xD;
      Canisius Wilhelmina ziekenhuis (Nijmegen) will not be part of this study. This study is&#xD;
      Investigator initiated with an unrestricted grant from Boehringer Ingelheim (subsidising&#xD;
      party). This study is also to be noted as a Post Authorisation Safety Study (PASS). Patients&#xD;
      1000 patients with an indication for NOAC, who underwent successful PCI with Drug Eluting&#xD;
      Stent (DES) in the setting of ACS will be included and randomised at each of the 4 centers of&#xD;
      the ZON-HR. After randomisation, patients will be treated with Dual therapy with&#xD;
      Dabigatran/Clopidogrel or with Dabigatran/ Ticagrelor. A total of 1000 patients in 4 centers&#xD;
      will be included: 250 patients in each center. In each center inclusion and randomisation&#xD;
      will be executed within 48 hours after PCI. Inclusions are expected to be done within 1 year.&#xD;
      After inclusion of the interventional (Dual therapy with Dabigatran/Ticagrelor) and control&#xD;
      group (Dual therapy with Dabigatran/Clopidogrel), follow-up of 1 year is planned.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 23, 2020</start_date>
  <completion_date type="Anticipated">July 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bleeding</measure>
    <time_frame>12 months</time_frame>
    <description>Bleeding defined as BARC bleeding score ≥2</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Myocardial Infarction</measure>
    <time_frame>12 months</time_frame>
    <description>Myocardial Infarction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cerebrovascular accident</measure>
    <time_frame>12 months</time_frame>
    <description>Cerebrovascular accident, ischemic of haemorrhagic</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic Embolic Complications</measure>
    <time_frame>12 months</time_frame>
    <description>Systemic Embolic Complications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death</measure>
    <time_frame>12 months</time_frame>
    <description>Death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Combined endpoint of ischemic events</measure>
    <time_frame>12 months</time_frame>
    <description>All secondary outcomes combined into one endpoint</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Myocardial Ischemia</condition>
  <condition>Myocardial Infarction</condition>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Dabigatran/Clopidogrel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patiënt receive standard care, with dabigatran + clopidogrel 75mg once daily up to 12 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dabigatran/Ticagrelor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patiënt receive standard care, with dabigatran + ticagrelor 90mg twice daily up to 12 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dabigatran + Ticagrelor</intervention_name>
    <description>Patiënt interventional treatment, with dabigatran + ticagrelor (Brilique) 90mg twice daily up to 12 months.</description>
    <arm_group_label>Dabigatran/Ticagrelor</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dabigatran + clopidogrel</intervention_name>
    <description>Patiënt interventional treatment, with dabigatran + clopidogrel (plavix) 75mg once daily up to 12 months.</description>
    <arm_group_label>Dabigatran/Clopidogrel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  Patients having an indication for a NOAC or will start with oral anticoagulation&#xD;
             (NOAC). Permanent, persistent or paroxysmal atrial fibrillation are eligible.&#xD;
&#xD;
          -  PCI and successful stenting with DES for ACS (unstable angina pectoris, NSTEMI, STEMI)&#xD;
&#xD;
          -  Written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients unable or unwilling to comply with the protocol or with life expectancy&#xD;
             shorter than the duration of the study&#xD;
&#xD;
          -  Glomerular filtration rate &lt; 30 ml/min&#xD;
&#xD;
          -  Heart valve prosthesis (mechanical or biological)&#xD;
&#xD;
          -  Cardiogenic shock&#xD;
&#xD;
          -  Contra-indication for Dabigatran, Ticagrelor or Clopidogrel&#xD;
&#xD;
               -  Liver dysfunction (ALAT, ASAT, Alkaline phosphatase &gt; 3x upper limit of normal)&#xD;
                  or liver disease (like hepatitis A, B, C)&#xD;
&#xD;
               -  Lesion or condition with a significant risk of serious bleeding, such as; current&#xD;
                  or recent gastrointestinal ulceration; malignant neoplasms with more bleeding&#xD;
                  risk; recent brain / spinal cord injury; recent surgery on the brain, spinal cord&#xD;
                  or eyes; recent or history of intracranial haemorrhage; oesophageal varices;&#xD;
                  arteriovenous malformations; vascular aneurysms; o severe intraspinal or&#xD;
                  intracerebral vascular abnormalities.&#xD;
&#xD;
               -  comedication with cyclosporine, itraconazole, ketoconazole (systemic) and&#xD;
                  glecaprevir / pibrentasvir, dronedarone, rifampicine, carbamazepine, St. Jan's&#xD;
                  wort or phenytoin o Comedication with tacrolimus is not recommended.&#xD;
&#xD;
          -  Allergy to for Dabigatran, Ticagrelor or Clopidogrel&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Significant thrombocytopenia (platelet count &lt; 50x10 9/L)&#xD;
&#xD;
          -  Major bleeding according to BARC ≥3 within the past 6 months.&#xD;
&#xD;
          -  Weight &lt; 50 kg&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Zuyderland MC</name>
      <address>
        <city>Heerlen</city>
        <state>Limburg</state>
        <zip>6419PC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patty Winkler</last_name>
      <phone>+31 6 53368084</phone>
      <email>p.winkler@zuyderland.nl</email>
    </contact>
    <investigator>
      <last_name>Jasper Luijkx</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 23, 2020</study_first_submitted>
  <study_first_submitted_qc>December 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 30, 2020</study_first_posted>
  <last_update_submitted>April 29, 2021</last_update_submitted>
  <last_update_submitted_qc>April 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dabigatran</mesh_term>
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Ticagrelor</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

